Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients
Journal Title: Journal of Krishna Institute of Medical Sciences University - Year 2015, Vol 4, Issue 1
Abstract
Background: Iron overload is a predictable and lifethreatening complication in patients with thalassemia. Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major. The development of a safe and effective chelator has been the goal for many years. Aims and Objective: It was aimed to compare the effect of deferiprone, deferoxamine and combination of deferiprone and deferoxamine on serum ferritin value in betathalassemia patients. Material and Methods: This controlled clinical trial was conducted on 46 major beta-thalassemic patients. Fifteen patients in deferiprone group received deferiprone 75mg/kg/day three times a day orally. Nineteen patients in deferoxamine group received deferoxamine 30-50 mg/kg/day subcutaneously for 8-12 hours/day and 5 days per week. Twelve patients in combined therapy group received deferiprone 75 mg/kg/day three times a day orally with deferoxamine 30–50 mg/kg subcutaneously every other day. Serum ferritin value was th th measured at the beginning and at the end of 6 and 12 months of study. Results: The mean of serum ferritin value in deferiprone group insignificantly increased from 2731± 1398.5 μg/L at the beginning to 2788.5 ± th 978.6 μg/L and to 3331.8 ± 1833.9 μg/L at the end of 6 th and 12 months of study, respectively. The mean of serum ferritin value in deferoxamine group insignificantly increased from 2883.5 ± 1598.1 μg/L at the th beginning to 2935.3 ± 1258.2 μg/L at the end of 6 month of study and decreased to 2773.8 ± 1216.1 μg/L th and 12 month of study. The mean of serum ferritin level in combined therapy group significantly decreased from 7498.7 ± 3512.9 μg/L at the beginning to 4839.9 ± 2698.2 μg/L (P < 0.001) and to 4298.2 ± th th 2288.7 μg/L (P < 0.001) at the end of 6 and 12 months of study, respectively. Conclusion: Combined therapy significantly decreases serum ferritin level. Study suggests deferiprone as a significant addition to support therapy in patients with betathalassemia major on regular transfusion regimens.
Authors and Affiliations
Nargesbeygom Mirbehbahani , Azam Jahazi , Haniye Mohsenkhah Amlashi , Naser Behnampour
Keywords
Related Articles
- EP ID EP100149
- DOI -
- Views 106
- Downloads 0
Deep Vein Thrombosis with First Episode Catatonia: A Case Report
Catatonia is a medical emergency condition with varied causative factors. Subsequent medical complications of catatonia put the patient to high risk of morbidity and mortality. Earlier studies show mortality rates up...
A Comparative Study between Cystoscopy and Cystography in Detecting Bladder Diverticulae in Patients with Benign Prostatic Hyperplasia
Background: Bladder diverticulae are mucosal outpunching and majority are acquired and secondary to either benign prostatic hypertrophy or the upper motor type of neurogenic bladder. Aim & Objectives: This study...
Henle's Spine - an Anatomical Landmark for Approaching Various Foramina in the Base of Skull
Background: Surface landmarks of the temporal bone are related to various anatomical structures. The surgical exposure of the middle cranial fossa, transpetrosal and transmastoid approaches for skull base surgeries would...
Let's Talk About Depression but More Needs to Be Done – Lessons from the Jan Man Swastha Program
-
Study of Changes in Knowledge of Primary Health Care among Medical Interns Attending the Community Medicine Posting
Background: Internship is the best period foracquiring practical knowledge and skills in communitymedicine to become a successful primaryhealth care physician. Effectiveness ofinternship has been questioned in many resea...